Zawilska K, Elikowski W, Turowiecka Z, Zozulinska M, Grzywacz A, Przybyl L, Vinazzer H
Department of Haematology, Academy of Medicine, Poznan, Poland.
Thromb Res. 1995 May 1;78(3):211-6. doi: 10.1016/0049-3848(95)00050-2.
Hemovasal produced by Manetti-Roberts, Florence, Italy, is a glycosaminoglycan obtained from porcine intestinal mucosa which belongs to the family of heparan sulfates. The substance was examined On 36 male survivors of myocardial infarction with an interval of at least 6 months after the acute event. No anticoagulants were given and ASA was withdrawn at least 2 weeks before the trial. Hemovasal was administered in 3 different i.m. doses as single injections. A further group received a daily oral dose of 300 mg for one week. A comparable placebo group of patients as well as a group of healthy volunteers was run in parallel. The coagulation profile showed only a slight prolongation of the aPTT, a trace of diminution of Antithrombin III and no activation of Heparin cofactor II. The fibrinolytic system showed an enhancement of the diurnal increase of t-PA without an alteration of the total increase of this activity. There was a considerable and highly significant diminution of the PAI-1 activity. This was dose dependent and could be found after i.m. as well as after oral administration. It was assumed that the thrombolytic effect which was repeatedly described was a consequence of the diminution of PAI-1.
由意大利佛罗伦萨的马内蒂 - 罗伯茨公司生产的血血管素是一种从猪肠黏膜中提取的糖胺聚糖，属于硫酸乙酰肝素家族。对36名心肌梗死男性幸存者进行了研究，急性事件发生后至少间隔6个月。未给予抗凝剂，且在试验前至少2周停用阿司匹林。血血管素以3种不同的肌肉注射剂量单次注射给药。另一组患者口服300毫克，每日一次，共服用一周。同时设立了一个可比的安慰剂组患者以及一组健康志愿者作为对照。凝血指标显示，活化部分凝血活酶时间（aPTT）仅略有延长，抗凝血酶III略有减少，肝素辅因子II未被激活。纤维蛋白溶解系统显示，组织型纤溶酶原激活物（t-PA）的日增量增强，但该活性的总增量未改变。纤溶酶原激活物抑制剂-1（PAI-1）活性显著且高度显著降低。这与剂量有关，肌肉注射和口服给药后均可发现。据推测，反复描述的溶栓作用是PAI-1减少的结果。
